JMJD3 participates in activation and apoptosis of IFN-αand TLR7-induced B cells
10.3969/j.issn.1000-484X.2015.07.005
- VernacularTitle:JMJD3参与IFN-α和TLR7诱导的B细胞活化及凋亡
- Author:
Hongye FAN
;
Baohui LI
;
Fei LIU
;
Deshan REN
;
Yayi HOU
;
Changlin ZHOU
- Publication Type:Journal Article
- Keywords:
Bcells;
IFN-α;
Toll-like receptor 7;
Jumonji domain containing 3 histon lysine demethylase
- From:
Chinese Journal of Immunology
2015;(7):890-894
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of histone demethylase JMJD3 on B cell activation and apoptosis.Methods:B cells were sorted and purified from the peripheral blood of healthy people and SLE patients by using magnetic bead.After B cells were treated with IFN-αor R848 or IFN-α+R848,the percentages of CD86+B cells,CD69+B cells,CD86+Annexin V+B cells and CD69+Annexin V+B cells were detected by flow cytometry.The expression of JMJD3 was detected by Real Time PCR and Western blot.Results:The purity of sorted B cells was up to 95%.IFN-αenhanced both the activation and apoptosis and the JMJD3 expression of TLR7-activated B cells.The expression of JMJD3 was dependent on MAPK signal pathway,but not the NF-κB signaling pathway.Moreover,JMJD3 was highly expressed in B cells of peripheral blood from SLE patients compared to those from healthy people.Furthermore,JMJD3 inhibitors could inhibit the activation and apoptosis of IFN-αand R848 activated B cells.Conclusion:JMJD3 participated in the activation and apoptosis of IFN-αand TLR7-induced B cells, suggesting JMJD3 inhibitors may possess therapeutic effect for alleviating symptom of SLE.
